Journals / Nöropsikiyatri Arşivi / 2014 / Cilt: 51 - Sayı: 4

A case of risperidone ınduced stuttering as a paradox

Bir paradoks olarak risperidon kullanımına bağlı kekemelik olgusu

Pages
403–404
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As well as the use of risperidone for the treatment of stuttering, stuttering adverse effect seems to be interesting as a paradox.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The main feature of stuttering is the disturbance in terms of both timing and fluency of speech inappropriate with the age.
📊
Key Findings & Data:Risperidone is a strong antagonist of dopamin 2 (D2) and serotonin 2A (5 HT2A) and shows a high affinity for α1 and α2 noradrenaline receptors.
💡
Conclusion & Impact:As well as the use of risperidone for the treatment of stuttering, stuttering adverse effect seems to be interesting as a paradox.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The main feature of stuttering is the disturbance in terms of both timing and fluency of speech inappropriate with the age. This disturbance is characterized with the repetition and prolongation of sounds and syllables. There are two types of stuttering as acquired and developmental. Acquired stuttering may begin suddenly at any age and may be seen rarely due to the adverse effects of drugs. Stuttering induced by antipsychotics may develop very rarely. Risperidone is a strong antagonist of dopamin 2 (D2) and serotonin 2A (5 HT2A) and shows a high affinity for α1 and α2 noradrenaline receptors. It’s used in a wide spectrum including psychotic disorders, mood disorders, and behavioral disorders, even for the treatment of stuttering. Risperidone treats the symptoms of stuttering by the antagonism of D receptors with an 2increase in striatal metabolism. In literature, we haven’t observed any other case reports except the two stuttering cases with psychotic disorders due to the short term and high-dose risperidone treatment. In our case, stuttering adverse effect of chronic low-dose risperidone treatment is remarkable that is discussed for the first time. As well as the use of risperidone for the treatment of stuttering, stuttering adverse effect seems to be interesting as a paradox.

Özet

Kekemeliğin temel özelliği, bireyin konuşmasının gerek akıcılık, gerekse zamanlama yönünden yaşına uygun olmayan biçimde bozulmasıdır. Bu bozukluk seslerin ve hecelerin sık sık yinelemeleri ve uzatılmaları ile belirlidir. Kekemeliğin edinsel ve gelişimsel olarak iki tipi mevcuttur. Edinsel kekemelik herhangi bir yaşta aniden başlayabilmektedir ve ilaç yan etkilerine bağlı olarak nadir de olsa edinsel kekemelik görülebilmektedir. Antipsikotiklere bağlı kekemelik ise çok nadir gelişmektedir. Risperidon dopamin 2 (D2) ve serotonin 2A (5 HT2A) reseptörlerinin güçlü antagonisti olup, noradrenalin α1 ile α 2 reseptörlerine yüksek afinite göstererek etki etmektedir. Psikotik bozukluklar, duygudurum bozuklukları ve davranım bozuklukları hatta kekemelik tedavisi dahil olmak üzere geniş bir spektrumda kullanılmaktadır. Risperidon, D2 reseptör antagonizmasıyla striatal metabolizmayı artırarak kekemelik semptomlarını iyileştirmektedir. Literatürde psikotik bozukluğu olan kısa süreli ve yüksek doz risperidon tedavisine bağlı gelişen iki kekemelik olgusu dışında başka vaka sunumuna rastlanılmamıştır. Olgumuzda ise kronik düşük doz risperidon kullanımı sonrası gelişen kekemelik yan etkisi dikkat çekici olup ilk kez tartışılmıştır. Risperidon’un kekemelik tedavisinde kullanılmasının yanı sıra kekemelik yan etkisinin de bulunması bir paradoks olarak ilginç görünmektedir.

🔖

Cite This Article

ATAY, İ. M., TANRITANIR, B., AKPINAR, A., DEMİRDAŞ, A. (2014). A case of risperidone ınduced stuttering as a paradox. Nöropsikiyatri Arşivi, Cilt: 51 - Sayı: 4, 403–404. https://ajindex.com/articles/292532

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. American Psychiatric Association. Diagnostic and statistical ma- nual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association; 2000
  2. Brady JP. Drug-induced stuttering: a review of the literature. J Clin Psychopharmacol 1998; 18:50-54. [CrossRef] 3. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry Seki- zinci Baskı Aydın H, Bozkurt A, çev. Editörü. Ankara: Güneş Kitabe- vi; 2007
  3. Yadav DS. Case Report: Risperidone induced stuttering. General Hospital Psychiatry 2010; 32:559.e9-559.e10
  4. Nurnberg HG, Greenwald B. Stuttering: an unusual side effect of phenothiazines. Am J Psychiatry 1981; 138:386-387. [CrossRef] 6. Margetic B, Aukst-Margetic B, Krajinovic B. A case of stuttering during treatment with levomepromazine. Psychopharmacol Bull 2009; 42:8-10
  5. Bar KJ, Hager F, Sauer H. Olanzapine and clozapine induced stuttering: a case series. Pharmacopsychiatry 2004; 37:131-134. [CrossRef] 8. Costa D, Kroll R. Stuttering: an update for physicians Canadian Medical Association Journal 2000; 162:13
  6. İbiloğlu AO. Kekemelik. Psikiyatride Güncel Yaklaşımlar-Current Approaches in Psychiatry 2011; 3:704-727
  7. Felsenfeld S, Kirk KM, Zhu G, Statham DJ, Neale MC, Martin NG. A study of the genetic and environmental etiology of stuttering in a selected twin sample. Behav Genet 2000; 30:359-366. [CrossRef] 11. Burd L, Kerbeshian J. Stuttering and stimulants (letter) J. Clin. Ps- ychopharmacol 1991; 11:72-73. [CrossRef] 12. Wu JC, Maguire G, Riley G, Lee A, Keator D, Tang C, Fallon J, Najafi A. Increased dopamine activity associated with stuttering. Neuro- report 1991; 8:767-770. [CrossRef] 13. Maguire GA. The dopamine hypothesis of stuttering and its tre- atment implications. Presented at Collegium Internationale Neuro-Psychopharmacologicum Brussels, Belgium, July 2000.